Ro-3306

Catalog No.S7747

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Cited by 5 Publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647

Sci Rep, 2017, 7:41950

PubMed: 28176818

3 Customer Reviews

HeLa cells were untreated or treated with either colcemid (10 μg/ml for 16 h), RO-3306 (9 μM for 16 h), or both colcemid and RO-3306, as indicated. Cells were then lysed, and proteins were detected by Western analysis.

J Cell Biol, 2015, 209(2): 221-34 . Ro-3306 purchased from Selleck.

A, Expression of IFIT3 in HeLa cells pretreated with 5 μM RO-3306 for 12 hours and then stimulated with type I IFN (1,000 units/ml) for 8 hours. The cells were collected and total RNA was extracted for the detection of IFIT3 mRNA. Results are the relative expression levels of IFIT3 mRNA normalized to endogenous GAPDH mRNA levels. B, Expression of IFI27 in HeLa cells measured in the same samples as in A.

Arthritis Rheumatol, 2016, 68(5):1222-32.. Ro-3306 purchased from Selleck.
AML cells were treated with AZ20 in the absence or presence of RO-3306 (RO) for 24 h. Cells were then subjected to annexin V-FITC/PI staining and flow cytometry analyses. Combined treatment was compared to AZ20 treatment alone using pair-wise two-sample t-test. ***Indicates p < 0.001.

Sci Rep, 2017, 7:41950. Ro-3306 purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human NCI-SNU-1 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzNyOUWg{txO	NXLXOppiW0GQR1XS
human H460a cells	NWj1RpVYWHKxbHnm[ZJifGmxbjDhd5NigQ>?		M{j1O2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NIEh[2WubIOsJGlEPTB;MT6wOEDPxE1?	MW[xO\|MxOzR{MR?=
human MDA435 cells	NHK5WY1Rem:uaX\ldoF1cW:wIHHzd4F6		MVjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQUSzOUBk\WyuczygTWM2OD1zLkG0JO69VQ>?	NHXKOnYyPzNyM{SyNS=>
human HCT116 cells	M1vYSHBzd2yrZnXyZZRqd25iYYPzZZk>		MlHsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MT6xOEDPxE1?	MmWwNVc{ODN2MkG=
human H4 cell	NWG5OGdNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUi3OUDPxE1?	M33tXHNCVkeHUh?=
human PA-1 cell	MkjaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGTL[llKdmirYnn0bY9vKG:oIHj1cYFvKFCDLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIzPjV2IN88US=>	NYTFWFZiW0GQR1XS
human T98G cell	M33oWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlfKTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zOlgyOiEQvF2=	M1;tWHNCVkeHUh?=
human SW1710 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUPJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlE1ODhizszN	MX3TRW5ITVJ?
human U251 cell	MknES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF3mRWtKdmirYnn0bY9vKG:oIHj1cYFvKFV{NUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY{PzdzIN88US=>	NUTwPFQxW0GQR1XS
human ALL-PO cell	NIG4XFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H589yNKEmFNUC9NU46ODhzMzFOwG0>	M3X2dXNCVkeHUh?=
human RKO cells	MV3Qdo9tcW[ncnH0bY9vKGG\|c3H5		MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyxiSVO1NF0zKM7:TR?=	M2\S[lE4OzB\|NEKx
human SK-N-DZ cell	NVn3c45RT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYqxNXBxUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yMUi3OkDPxE1?	NGPqeI1USU6JRWK=
human A4-Fuk cell	NInt[GtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYnO[ndJUW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB3NkC0JO69VQ>?	M3HoRXNCVkeHUh?=
human SW480 cells	NX24eFBHWHKxbHnm[ZJifGmxbjDhd5NigQ>?		Mor0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{S4NEBk\WyuczygTWM2OD1{LkKg{txO	NWnRU5RGOTd\|MEO0NlE>
human 639-V cell	MnPkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk\JTY5pcWKrdHnvckBw\iCqdX3hckA3OzlvVjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlc2OzdizszN	M2P6[3NCVkeHUh?=
human Hs-578-T cell	NYXRWpo4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NX3CUnhjUW6qaXLpeIlwdiCxZjDoeY1idiCKcz21O\|guXCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMke3PVkh\|ryP	NUCz[lN4W0GQR1XS
human UM-UC-3 cell	NFTqNYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIX2dXZKdmirYnn0bY9vKG:oIHj1cYFvKFWPLWXDMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5Nige,:jDDJR\|UxRTJwN{O5N\|Yh\|ryP	MmPyV2FPT0WU
human BPH-1 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4[1V2lvcGmkaYTpc44hd2ZiaIXtZY4hSlCKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlk4PDV3IN88US=>	MomwV2FPT0WU
human 5637 cell	NWGyfm1YT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHXCN5VKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA5PTN{IN88US=>	MWXTRW5ITVJ?
human 8-MG-BA cell	NUfTXmFPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3rzOGlvcGmkaYTpc44hd2ZiaIXtZY4hQC2PRz3CRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:Oy5zNEC0PUDPxE1?	M2fQ[HNCVkeHUh?=
human HCT116 cells	Mk\ZR5l1d3SxeHnjxsBie3OjeR?=	MVu1JIRigXN?	NU\GdZlPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDViZHH5d{BjgSCPVGOgZZN{[XoxvJygTWM2OD1\|LkKg{txO	M{DaSlIzOzJ4MU[4
human LB1047-RCC cell	NGrmNohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ\|NUCxJO69VQ>?	M3;WUnNCVkeHUh?=
human KOSC-2 cell	NHm4WZJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3niUWlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41PDZ4NkKg{txO	NVLMTGJTW0GQR1XS
human COR-L88 cell	NX3D[IxqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml3FTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{41PzV6MzFOwG0>	MkDnV2FPT0WU
human PSN1 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M370XWlvcGmkaYTpc44hd2ZiaIXtZY4hWFOQMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVA5ODVizszN	NX3ZO5pvW0GQR1XS
human LXF-289 cell	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlIyPzZizszN	MVPTRW5ITVJ?
human MN-60 cell	NEDUe5lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkXuTY5pcWKrdHnvckBw\iCqdX3hckBOVi14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuN\|c3OjNizszN	MnT5V2FPT0WU
human NEC8 cell	M3nLXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkL4TY5pcWKrdHnvckBw\iCqdX3hckBPTUN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60O\|A4PiEQvF2=	NIfKNXVUSU6JRWK=
human SJSA1 cells	Mnj1VJJwdGmoZYLheIlwdiCjc4PhfS=>		NInXd4ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPKV2EyKGOnbHzzMEBKSzVyPUSuOVUh\|ryP	NFO2bJIyPzNyM{SyNS=>
human NCI-H2405 cell	M1yyemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXTZSGJIUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1ODViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke0OFk{KM7:TR?=	M{TzPHNCVkeHUh?=
human YH-13 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWHiXWV1UW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPzV5N{[g{txO	MVjTRW5ITVJ?
human SK-MEL-2 cell	M{PwNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnqyTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODl4M{Kg{rxu	MWDTRW5ITVJ?
human NB13 cell	M4jMNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFfUPZRKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlMzPzh4IN88US=>	NEnDU3pUSU6JRWK=
human GAMG cell	NUjyWVJVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEjhbHJKdmirYnn0bY9vKG:oIHj1cYFvKEeDTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM4OTVizszN	NYPaVnd3W0GQR1XS
human NCI-H1792 cell	NUHDbVBWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDd7NUSg{txO	MoHqV2FPT0WU
human KP-4 cell	M1\Mcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEHKfplKdmirYnn0bY9vKG:oIHj1cYFvKEuSLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY6QDJ\|IN88US=>	NXfjd\|hOW0GQR1XS
human HGC-27 cell	Ml;ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhISy1{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuO\|MxPzdizszN	NHLmO2xUSU6JRWK=
human GCT cell	M3\0VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2Lre2lvcGmkaYTpc44hd2ZiaIXtZY4hT0OWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT64OVEzOSEQvF2=	NY\VbZZMW0GQR1XS
human PFSK-1 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NF62elBKdmirYnn0bY9vKG:oIHj1cYFvKFCIU1utNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDZzNkig{txO	NETTSo5USU6JRWK=
human A172 cell	NEjOR4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXu2UJlkUW6qaXLpeIlwdiCxZjDoeY1idiCDMUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46ODd7IN88US=>	MlnSV2FPT0WU
human HO-1-N-1 cell	NUjIXXRnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYTJcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PTR{NTFOwG0>	Mm\4V2FPT0WU
human HN cell	NXrkOFVKT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYHJcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57N{C5O{DPxE1?	NV;ISY96W0GQR1XS
human IST-MES1 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUHldo5NUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe1NlEh\|ryP	NV\Q[nhmW0GQR1XS
human TGW cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWXJcohq[mm2aX;uJI9nKGi3bXHuJHRIXyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMEW2PFIh\|ryP	NV;MZox3W0GQR1XS
human COR-L23 cell	NVrWflljT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MofYTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEKzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4{PzN3IN88US=>	NGTId4lUSU6JRWK=
human D-566MG cell	NIHUUY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF\CVJBKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njd6OEezJO69VQ>?	NIfScmRUSU6JRWK=
human SKG-IIIa cell	MmDlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHNMTy2LSVnhJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok45PTV5MjFOwG0>	MYLTRW5ITVJ?
human NCI-H446 cell	NUXJXXFmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIfLU4tKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQ3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yMUixJO69VQ>?	NHThVWxUSU6JRWK=
human KYSE-270 cell	NEOz[ZhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF\HeFNKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNlcxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yM{i3NkDPxE1?	M1jvcnNCVkeHUh?=
human CAL-39 cell	MkHsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHfr[4VKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzV{NDFOwG0>	MnrrV2FPT0WU
human IST-SL1 cell	M3XxSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NU\3SIVwUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StV2wyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py52M{O0PUDPxE1?	NWP4PJp{W0GQR1XS
human SF539 cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNHPTN7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz61OVE6PyEQvF2=	NUHsTYlVW0GQR1XS
human TE-1 cell	NVuxcJRrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml;JTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz64PVA6OSEQvF2=	M1HlW3NCVkeHUh?=
human NB10 cell	Mnz0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmPITY5pcWKrdHnvckBw\iCqdX3hckBPSjFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz65PFc2QCEQvF2=	M3rZenNCVkeHUh?=
human 8505C cell	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHTRb3JKdmirYnn0bY9vKG:oIHj1cYFvKDh3MEXDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{46QThzNzFOwG0>	MUfTRW5ITVJ?
human DB cell	NEnMV4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2XocmlvcGmkaYTpc44hd2ZiaIXtZY4hTEJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkCxNVMyKM7:TR?=	MXPTRW5ITVJ?
human NCI-H28 cell	M2PIW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlU6QDh2IN88US=>	NGXSe5lUSU6JRWK=
human LOXIMVI cell	NY\EeGt[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHrk[XdKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjZ\|N{CxJO69VQ>?	NWHmNlUxW0GQR1XS
human ME-180 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX\CUIxNUW6qaXLpeIlwdiCxZjDoeY1idiCPRT2xPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF05NjhyM{m1JO69VQ>?	NYDTSXpTW0GQR1XS
human ES3 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmnjTY5pcWKrdHnvckBw\iCqdX3hckBGWzNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkGyO\|k1KM7:TR?=	M4Xuc3NCVkeHUh?=
human SK-N-FI cell	NVfaPHJvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQyPjl7IN88US=>	M13PZnNCVkeHUh?=
human NBsusSR cell	NGfRW4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4DIfmlvcGmkaYTpc44hd2ZiaIXtZY4hVkK\|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVExNjJ\|MUig{txO	MoflV2FPT0WU
human MCF7 cell	NVe1b29oT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF7aZXFKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4yQDR7IN88US=>	MXjTRW5ITVJ?
human A549 cell	M1TDU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMT6yNFYh\|ryP	Ml\KV2FPT0WU
human HuP-T4 cell	NWjveFhYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVf2TmlMUW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC52MkexJO69VQ>?	M{nlOnNCVkeHUh?=
human HSC-2 cell	NEi2WYtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF;6cJRKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEtPzh2MjFOwG0>	Mn;1V2FPT0WU
human A253 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{TU[WlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ3MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUG1MlI5OzRizszN	Mo\HV2FPT0WU
human HCT-116 cell	M2T6bWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkLmTY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUiuNFA1OyEQvF2=	MnvJV2FPT0WU
human HCT-116 cell	MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIrEPGFKdmirYnn0bY9vKG:oIHj1cYFvKEiFVD2xNVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS54Nkig{txO	MWLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand CDK assay: The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
Cell Research:^[3]	+ Expand Cell lines: MDA-MB-231 cell line Concentrations: 20 μM Incubation Time: 72 h Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength. (Only for Reference)

Kinase Assay:^[1]

+ Expand

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

+ Expand

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products0

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 5 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products0

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 5 Publications

3 Customer Reviews

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)